glp-1 for mash receptor agonists improve mostly via extrahepatic actions: 1️⃣ CNS appetite control → weight loss → ↓ systemic inflammation 2️⃣ ↓ Chylomicron synthesis & improve lipid metabolism 3️⃣ Bind… Incretin-based therapies in MASLD/MASH: from
Description
Who should not use GLP-1 therapy
The lack of effect of exenatide on the primary endpoints could be related to the severity profile of the study participants whose baseline alcohol intake was lower than what is reported in other clinical pharmacotherapy alcohol trials [118, 119]
GLP-1RAs may benefit COPD patients by acting directly on the lung from mechanisms such as reducing the inflammatory response, improving oxidative stress, regulating protease/anti-protease imbalance, improving airway mucus homeostasis, and reducing airway remodeling
Lower concentration of hippocampal N-acetylaspartate in familial bipolar I disorder
10.1016/j.diabres.2012.10.024 46
